Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brite Eye Drops is a multi-ingredient ophthalmic solution developed and marketed by Pharmtak. It is primarily indicated for the symptomatic relief of eye redness, congestion, and minor irritation caused by environmental factors such as dust, smoke, or eye strain. The formulation typically contains a combination of sympathomimetic amines, including naphazoline hydrochloride and phenylephrine hydrochloride, which act as vasoconstrictors by stimulating alpha-adrenergic receptors in the conjunctival blood vessels. This action reduces swelling and redness. Additionally, the formulation incorporates cooling agents such as camphor and menthol, which serve as mild counter-irritants to provide a soothing sensation and immediate relief from ocular discomfort. Pharmtak also markets a tablet version under the same brand name, which is formulated as a nutritional supplement containing antioxidants like lutein and zeaxanthin to support overall eye health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Brite Eye Drops.